Efficacy of Treatments for Relapsed/Refractory Chronic Lymphocytic Leukemia
Author Information
Author(s): Kim Jinchul, Cho Jinhyun, Lim Joo Han, Lee Moon Hee
Primary Institution: Department of Hematology-Oncology, Inha University College of Medicine and Hospital
Hypothesis
This network meta-analysis aimed to evaluate the relative efficacy of systemic treatments in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), focusing on key genetic mutations.
Conclusion
The study found that venetoclax plus rituximab and zanubrutinib are the most effective treatments for R/R CLL, with efficacy varying based on genetic mutations.
Supporting Evidence
- Venetoclax plus rituximab and zanubrutinib showed the lowest hazard ratios for progression-free survival.
- Zanubrutinib was the most effective treatment for patients with 17p deletion/TP53 mutations.
- Venetoclax plus rituximab was the best treatment for patients without these mutations.
Takeaway
This study looked at different treatments for a type of blood cancer and found that some combinations work better than others, especially depending on the patient's genes.
Methodology
A systematic literature review and Bayesian network meta-analysis were conducted to compare the efficacy of various treatments.
Limitations
The line of treatment across studies was inconsistent, and the analysis did not evaluate adverse events.
Participant Demographics
Patients had a median age ranging from 63 to 71 years, with varying prevalence of Rai stage III/IV disease and genetic mutations.
Statistical Information
Confidence Interval
95% CI
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website